Navigation Links
Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
Date:4/5/2011

CAMBRIDGE, Mass., April 5, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, today presented results from preclinical studies with 2F8, a murine analog of TRX518, a first-in-class immunomodulatory agent currently in a Phase 1 clinical study for the treatment of cancer. Preclinical data demonstrated anti-tumor efficacy in a murine model as a monotherapy, and further enhanced efficacy when used in combination with multiple classes of chemotherapeutics and with biologic agents such as anti-CTLA4.  Both TRX518, and its murine analog, 2F8, are monoclonal antibodies reactive with the glucocorticoid-induced tumor necrosis factor receptor (GITR) and are designed to enhance the immune system's anti-tumor response by enabling T lymphocytes and other cells to more effectively attack cancer cells. The preclinical data were presented as a poster and invited talk at the Keystone Symposia "Immunoregulatory Networks" meeting held in Breckenridge, Colorado.

"These data underscore the exciting promise of our anti-GITR program, highlighting the potential efficacy of TRX518's unique and powerful mechanism of action," said Tony deFougerolles, Tolerx's Chief Scientific Officer. "The preclinical data suggest that anti-GITR may have similar efficacy to anti-CTLA4, and that the combination of anti-GITR with anti-CTLA4 and chemotherapy may result in dramatic regression of established tumors."

The preclinical studies included combinations of an anti-GITR monoclonal antibody, chemotherapeutic drugs (including gemcitabine, cyclophosphamide, 5-fluorouracil, and doxorubicin), and an anti-CTLA4 monoclonal antibody.  These agents were evaluated for their anti-tumor efficacy against established tumors using a colon carcinoma model in mice.  Results and data included:

  • The combination of anti-GITR and chemotherap
    '/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Laureate Announces Manufacturing Agreement with Tolerx
2. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
3. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
4. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
5. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
6. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
7. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
8. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
9. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
10. GeoVax Presents Data at AIDS Vaccine 2008 Conference
11. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... signed into law H.R. 83, the Omnibus and ... the first time, made hydrocephalus a condition eligible ... Research Programs (CDMRP) administered by the Department of ... conjunction with its allies on Capitol Hill, is ...
(Date:12/24/2014)... 23, 2014 Pipette.com announces their ... followers can submit their #HolidayInTheLab pictures for a chance ... mates. , For those struggling to think of a ... Holiday in the Lab Contest provides the ideal holiday ... to send pictures of their chemistree, holiday sweaters, ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... Efficiency to the Advanced Performance of the A1 Series ... , MELVILLE, N.Y., Dec. 15 ... available, Nikon Instruments, Inc.,s ( www.nikoninstruments.com ) A1 series ... C software brings biological imaging to life. The ...
... ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ), ... proprietary product candidates primarily for the treatment of cancer, ... strategic options, including the sale or disposition of one ... business merger and other transactions that maximize the value ...
... NATICK, Mass., Dec. 15 Boston Scientific,Corporation (NYSE: ... and Drug,Administration (FDA) has approved the Express(R) SD Renal ... PTRA (percutaneous,transluminal renal angioplasty) in certain lesions of the ... low-profile, pre-mounted stent approved for use,in renal arteries in ...
Cached Biology Technology:Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities 2Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities 3ADVENTRX Exploring Strategic Options 2ADVENTRX Exploring Strategic Options 3ADVENTRX Exploring Strategic Options 4FDA Approves Boston Scientific's Express(R) SD Renal Stent System 2FDA Approves Boston Scientific's Express(R) SD Renal Stent System 3FDA Approves Boston Scientific's Express(R) SD Renal Stent System 4
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... have all but disappearedwere home to dozens of species of ... hundreds of species of flowers, and herds of roaming bison. ... by the University of Colorado Boulder has gotten a peek ... once called the tallgrass prairie home: the diverse assortment of ...
... AMHERST, Mass. Usually indigestion is a bad thing, ... Robert Vass at the University of Massachusetts Amherst recently ... partial degradation of a DNA replication protein is required ... one of the most highly controlled biological processes in ...
... Institute of Biotechnology have used the power of ... atomic movements. The research is helping to chart ... "glycomes" - the entire complement of carbohydrates within ... new understanding of these vital biomolecules which play ...
Cached Biology News:CU-Boulder-led team gets first look at diverse life below rare tallgrass prairies 2Biochemists find incomplete protein digestion is a useful thing for some bacteria 2Gaming technology unravels 1 of the most complex entities in nature 2Gaming technology unravels 1 of the most complex entities in nature 3
... to Peroxiredoxin 1 Peroxiredoxin (Prx) ... mammalian members have been known to ... apoptosis. Many isoforms (about 50 proteins), ... acid sequence homology, particularly amino-terminal region ...
... Heat activated ,• Eliminates nonspecific products ... Excellent specificity allows extension through DNA ... ,• Leaves an 'A' overhang ... of GeneChoice DNA Polymerase that remains ...
... beta Synuclein Synucleins are small, soluble ... in certain tumors. The family includes three ... gamma synuclein. The alpha and beta synuclein ... where they are seen mainly in presynaptic ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
Biology Products: